Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study

NCT07421258 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07421258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07421258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
February 9, 2026
Completion date
September 1, 2026
Enrollment
1,638 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis